
News and Publications
Publication Categories
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.
7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
7 Hills Pharma announces the first healthy volunteers dosed in its Phase 1 trial of 7HP349, an immunostimulant aimed to enhance immuno-oncology drugs and COVID-19 & influenza vaccines, improving immune responses and increasing effectiveness in older adults.
7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies
7 Hills Pharma secures broad USPTO patent protection for its integrin activators, positioning the company as a key partner for immuno-oncology and COVID-19 vaccine developers. FDA-approved IND trials set to begin soon.
7 Hills Pharma Highlights Cell Adhesion as Key to Improving Effectiveness of Covid-19 Vaccines and Immuno-Oncology Drugs At BIO Digital 2020 Online Conference
Discover how 7 Hills Pharma’s integrin activators enhance immunotherapies by boosting cell adhesion, improving COVID-19 vaccines, checkpoint inhibitors, and cancer treatments. Learn more from BIO Digital 2020.
7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
7 Hills Pharma’s integrin platform technology enhances immunotherapies, boosting COVID-19 vaccine efficacy and checkpoint inhibitors by improving cell adhesion for stronger immune responses. Learn more from BIO Digital 2020.
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
7 Hills Pharma forms a Scientific Advisory Board with top immuno-oncology experts to advance its integrin activator program, aiming to enhance checkpoint inhibitors and improve cancer immunotherapy effectiveness.
7 Hills Pharma Launches With $2 Million SBIR Grant in addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance
7 Hills Pharma secures a $2M SBIR grant from the NIH, alongside $4M in seed funding, to develop integrin activators that enhance cancer immunotherapy and improve checkpoint inhibitor effectiveness in treating solid tumors.